Filing summary
Entity and period: The supplied filing is PerkinElmer, Inc.’s Form 10-K for the fiscal year ended December 31, 2017 (52 weeks), ticker PKI—not a filing identifying the registrant as Revvity, Inc. The requested “2017 Q4” is covered in the annual filing; quarterly figures below are included where relevant. Unless otherwise noted, amounts are in U.S. dollars.
Business context and reporting period
PerkinElmer provided products, services, and solutions for diagnostics, life sciences research, environmental, food, industrial, and laboratory-services markets. It reported two segments: Discovery & Analytical Solutions and Diagnostics. Approximately 60% of fiscal 2017 sales were international.
Financial performance and key metrics
| Metric | FY 2017 | FY 2016 |
|---|---|---|
| Revenue | $2,257.0 million | $2,115.5 million |
| Gross profit / gross margin | $1,073.0 million / 47.5% | $1,013.4 million / 47.9% |
| Operating income from continuing operations / margin | $304.8 million / 13.5% | $283.1 million / 13.4% |
| Income from continuing operations | $156.9 million | $215.7 million |
| Net income | $292.6 million | $234.3 million |
| Diluted EPS, continuing operations | $1.42 | $1.96 |
| Diluted EPS, total | $2.64 | $2.12 |
| Cash from continuing operating activities | $292.2 million | $323.8 million |
| Capital expenditures | $39.1 million | $31.7 million |
- Segment revenue: Discovery & Analytical Solutions revenue was $1,578.5 million, up 4%; Diagnostics revenue was $678.5 million, up 13%. Segment operating income was $206.7 million and $149.6 million, respectively.
- Liquidity: Year-end cash and cash equivalents were $202.1 million, including $187.5 million held by non-U.S. subsidiaries. The company reported $363.6 million of additional borrowing capacity on its revolving facility. Current assets were $1,200.0 million and current liabilities were $950.9 million.
- Debt: Total carrying value of debt was approximately $2,006.1 million, including $217.3 million classified as current. This included $625.0 million drawn on the revolving facility and a $200.0 million term loan maturing December 2018. The company reported compliance with applicable debt covenants.
Material changes versus the prior comparable period
- Revenue rose 7%, including an estimated 2% contribution from acquisitions and divestitures and 0.4% from foreign exchange. Diagnostics growth reflected screening and applied-genomics demand, plus acquisitions; Discovery & Analytical Solutions benefited from laboratory services and environmental, food, and industrial markets.
- Gross margin declined 0.36 percentage points, primarily due to unfavorable product mix, partly offset by supply-chain improvements. Operating margin increased about 0.12 percentage points, with cost containment and productivity benefits partly offset by new-product investment.
- Continuing-operations income fell despite higher operating income. The principal unusual item was a $106.5 million discrete tax expense from the 2017 Tax Cuts and Jobs Act, contributing to a 47.1% effective tax rate versus 11.6% in 2016.
- Total net income increased partly because the company sold its Medical Imaging business in May 2017, recording a $179.6 million pretax gain. The sale generated $135.7 million of after-tax discontinued-operations and disposition income for the year.
- Continuing-operations cash flow declined $31.6 million. The company cited working-capital use, including increases in receivables and inventory. Investing cash outflow rose sharply due mainly to acquisition spending of $1,527.2 million.
- Fiscal 2017 included $12.7 million of restructuring and contract-termination charges. The company completed three acquisitions for total consideration of approximately $1.6 billion, including EUROIMMUN for about €1.2 billion.
Outlook, commentary, risks, and unusual items
- Management expected fiscal 2018 capital expenditures to be similar to fiscal 2017’s $39.1 million, focused on new products, operating processes, production capacity, and information technology. It expected continued strong R&D investment; the filing provides no clear consolidated revenue or EPS guidance.
- Management cited growth opportunities in diagnostics, earlier disease detection, laboratory services, and environmental and food testing. It also noted continued weakness in radioactive-reagent sales within life sciences research.
- Tax reform estimates remained preliminary. The $85.0 million transition-tax component was expected to be paid over eight years; management had not yet determined the accounting policy or reasonably estimated the effect of GILTI provisions.
- Key risks include acquisition integration and valuation, substantial debt and variable-rate exposure, currency movements, international and regulatory risks, dependence on timely product innovation, competition, and potential goodwill or intangible-asset impairment. Informatics was identified as having elevated impairment risk, though management did not expect a material impairment based on its assumptions.
- Environmental remediation accruals were $9.4 million at year-end, generally expected to be paid over as many as ten years. Management said ordinary-course legal contingencies were not expected to materially affect the financial statements, while noting outcomes remain uncertain.
- The fourth quarter included a $2.1 million pretax postretirement mark-to-market gain. Reported fourth-quarter continuing-operations loss was $38.4 million, reflecting the annual tax provision’s quarterly impact; the filing’s quarterly table reports fourth-quarter discontinued-operations and disposition loss of $2.7 million.
- The independent auditor gave unqualified opinions on the financial statements and internal control over financial reporting. The assessment excluded EUROIMMUN’s controls, representing approximately 30.7% of year-end assets and 0.6% of annual revenue.
Important facts for investors to verify
- Confirm the filing entity and ticker: the source is PerkinElmer, Inc. (PKI), notwithstanding the request metadata naming Revvity, Inc.
- Separate recurring continuing-operations earnings from the Medical Imaging disposal gain and assess the effect of the Tax Act charge on reported earnings and future cash taxes.
- Review acquisition performance and integration—particularly EUROIMMUN—and monitor the preliminary purchase-price allocations, acquired intangible amortization, goodwill, and contingent consideration.
- Assess refinancing and repayment needs, especially the $200.0 million term loan due in December 2018, variable-rate borrowings, covenant capacity, and cash availability across jurisdictions.
- Track cash conversion and working capital, given lower operating cash flow and higher receivables and inventory, alongside management’s 2018 investment plans.